Literature DB >> 30500997

Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay.

Enrico Munari1, Giuseppe Zamboni1,2, Giorgia Sighele1, Marcella Marconi1, Marco Sommaggio1, Gianluigi Lunardi3, Giulio Rossi4, Alberto Cavazza5, Francesca Moretta6, Eliana Gilioli2, Anna Caliò2, George J Netto7, Mohammad O Hoque8, Guido Martignoni2,9, Matteo Brunelli2, Paola Vacca10, Lorenzo Moretta10, Giuseppe Bogina1.   

Abstract

BACKGROUND: Evaluation of programmed cell death ligand 1 (PD-L1) expression can be made on both resection specimens and diagnostic biopsies; however, more than 30% of patients with advanced non-small cell lung cancer (NSCLC) do not have adequate histologic material to perform PD-L1 assays and require additional biopsies. In addition, in our practice, more than 16% of cases have cytological smears as the only available material. Our aim was to validate the PD-L1 immunocytochemistry assay on cytological smears and compare its accuracy with the results obtained from tissue cores and whole tumor sections using the clinically relevant cutoff of 50%.
METHOD: We compared the PD-L1 staining results of cytological smears to those from tissue cores or whole sections in 50 and 53 NSCLC cases, respectively, using the SP263 assay after scanning hematoxylin and eosin slides.
RESULTS: We found an overall agreement of 90.6% between cytological smears and whole sections; specifically, we found absolute concordance between smears with PD-L1 expressed in <10% and ≥50% of cells and whole sections with PD-L1 expressed in <50% and ≥50% of cells, respectively. In addition, slightly lower diagnostic accuracy was found for the cytological smears in comparison with the tissue cores, but the difference was not statistically significant. We found excellent intraobserver and good interobserver agreement in the evaluation of PD-L1 on smears.
CONCLUSION: Immunocytochemistry on cytological smears is a reliable method for determination of PD-L1 at the 50% cutoff when positive cells are <10% or ≥50%; for cases showing PD-L1 expression in 10% to 49% of cells, additional tissue sampling may be necessary.
© 2018 American Cancer Society.

Entities:  

Keywords:  PD-L1; comparison; cytology; lung cancer; smear

Mesh:

Substances:

Year:  2018        PMID: 30500997     DOI: 10.1002/cncy.22083

Source DB:  PubMed          Journal:  Cancer Cytopathol        ISSN: 1934-662X            Impact factor:   5.284


  18 in total

1.  Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients.

Authors:  C Kuempers; L I S van der Linde; M Reischl; W Vogel; F Stellmacher; M Reck; D Heigener; K F Rabe; J Kirfel; S Perner; L Welker
Journal:  Virchows Arch       Date:  2019-08-07       Impact factor: 4.064

2.  The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.

Authors:  Yang Wang; Junqi Wu; Jiajun Deng; Yunlang She; Chang Chen
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

Review 3.  Immunocytochemistry for predictive biomarker testing in lung cancer cytology.

Authors:  Deepali Jain; Aruna Nambirajan; Alain Borczuk; Gang Chen; Yuko Minami; Andre L Moreira; Noriko Motoi; Mauro Papotti; Natasha Rekhtman; Prudence A Russell; Spasenija Savic Prince; Yasushi Yatabe; Lukas Bubendorf
Journal:  Cancer Cytopathol       Date:  2019-05-03       Impact factor: 5.284

Review 4.  Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.

Authors:  Simona Sivori; Paola Vacca; Genny Del Zotto; Enrico Munari; Maria Cristina Mingari; Lorenzo Moretta
Journal:  Cell Mol Immunol       Date:  2019-02-18       Impact factor: 11.530

5.  PD-L1 CPS Scoring Accuracy in Small Biopsies and Aspirate Cell Blocks from Patients with Head and Neck Squamous Cell Carcinoma.

Authors:  Ajit S Paintal; Bruce E Brockstein
Journal:  Head Neck Pathol       Date:  2019-11-13

6.  Plasma complement C7 as a target in non-small cell lung cancer patients to implement 3P medicine strategies.

Authors:  Jae Gwang Park; Beom Kyu Choi; Youngjoo Lee; Eun Jung Jang; Sang Myung Woo; Jun Hwa Lee; Kyung-Hee Kim; Heeyoun Hwang; Wonyoung Choi; Se-Hoon Lee; Byong Chul Yoo
Journal:  EPMA J       Date:  2021-11-25       Impact factor: 6.543

Review 7.  Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.

Authors:  Lynette M Sholl
Journal:  Mod Pathol       Date:  2021-10-04       Impact factor: 7.842

Review 8.  Selected highlights of the 2019 Pulmonary Pathology Society Biennial Meeting: PD-L1 test harmonization studies.

Authors:  Sylvie Lantuejoul; Francesca Damiola; Julien Adam
Journal:  Transl Lung Cancer Res       Date:  2020-06

Review 9.  PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells.

Authors:  Silvia Pesce; Marco Greppi; Francesco Grossi; Genny Del Zotto; Lorenzo Moretta; Simona Sivori; Carlo Genova; Emanuela Marcenaro
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

Review 10.  PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens: A Comparison with Biopsies and Review of the Literature.

Authors:  Mohammed S I Mansour; Kajsa Ericson Lindquist; Tomas Seidal; Ulrich Mager; Rikard Mohlin; Lena Tran; Kim Hejny; Benjamin Holmgren; Despoina Violidaki; Katalin Dobra; Annika Dejmek; Maria Planck; Hans Brunnström
Journal:  Acta Cytol       Date:  2021-07-07       Impact factor: 2.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.